Core Viewpoint - Jiangsu Aidea Pharmaceutical Co., Ltd. has completed the registration of its name change to Jiangsu Aidea Pharmaceutical Group Co., Ltd. and has obtained a new business license [1] Group 1: Company Name Change - The company held its third board meeting and the second extraordinary shareholders' meeting on June 27 and July 14, 2025, respectively, where the proposal to change the company name was approved [1] - The English name has been changed from "Jiangsu Aidea Pharmaceutical Co., Ltd." to "Jiangsu Aidea Pharmaceutical Group Co., Ltd." [1] - The name change does not affect the stock abbreviation and stock code [1] Group 2: Business License and Registration - The company has completed the business registration change and obtained a new business license from the Yangzhou Market Supervision Administration [1] - The new business license details include: - Name: Jiangsu Aidea Pharmaceutical Group Co., Ltd. - Unified Social Credit Code: 913210006979433664 - Type: Joint-stock company (foreign investment, listed) - Legal Representative: Fu Helian - Registered Capital: 420.782808 million RMB - Establishment Date: December 15, 2009 - Address: No. 69, Xinganqian West Road, Hanjiang District, Yangzhou City [1] Group 3: Business Scope - The company's business scope includes drug research and development, production and sales, development, acquisition, processing, and sales of effective components from human urine protein, animal organs, and plant raw materials, as well as technology research and development, transfer, consulting, and services [1] - The company is also engaged in the import and export of general goods and technologies, subject to national regulations [1]

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 江苏艾迪药业集团股份有限公司（以下简称"公司"）于 2025 年 6 月 27 日 和 2025 年 7 月 14 日分别召开了第三届董事会第四次会议和 2025 年第二次临时 股东会，审议通过了《关于变更公司名称及修改<公司章程>的议案》，同意将公 司名称由"江苏艾迪药业股份有限公司"变更为"江苏艾迪药业集团股份有限公 司"，公司英文名称由："Jiangsu Aidea Pharmaceutical Co., Ltd."变更为"Jiangsu Aidea Pharmaceutical Group Co., Ltd."，并相应修改《公司章程》，详见公司于 2025 年 6 月 28 日、2025 年 7 月 15 日在上海证券交易所网站（www.sse.com.cn）、《证 券时报》披露的《江苏艾迪药业股份有限公司关于变更公司名称及修改<公司章 程>的公告》（公告编号：2025-029）、《江苏艾迪药业股份有限公司 2025 年第二 次临时股东会决议公告》（公告编号：2025 ...

Core Viewpoint - The HIV drug market in China is experiencing rapid growth due to an increasing number of patients, expanding insurance coverage, and rising payment capabilities among the affected population, with a projected market size of 5.836 billion yuan in 2024, reflecting a year-on-year growth of 30.2% [1][16]. Industry Overview - HIV drugs are antiviral medications aimed at treating AIDS, which is caused by the human immunodeficiency virus (HIV) that attacks the immune system [2]. - As of the end of 2024, there are approximately 1.355 million reported living HIV/AIDS patients in China, with 749,800 being HIV-infected and 605,200 being AIDS patients [1][4]. Market Dynamics - The Chinese HIV drug market is expected to maintain a growth rate of over 20% from 2021 to 2024, driven by the increasing number of patients and the expansion of medical insurance coverage [16]. - The self-paid drug market is projected to reach 3.787 billion yuan in 2024, growing by 47.5% year-on-year, while the free drug market is expected to be 2.049 billion yuan, with a growth of 7% [18]. Competitive Landscape - Gilead and GSK dominate the Chinese HIV drug market, holding a combined market share of 90%, while local companies like Frontier Biopharma and Aidi Pharmaceutical have a smaller market presence of less than 10% [22]. Development Trends - Future research in the global HIV drug market will focus on developing new drugs with better efficacy and safety, exploring new drug targets, and investigating new treatment methods such as gene therapy and immunotherapy [24].

江苏世纪同仁律师事务所 关于江苏艾迪药业股份有限公司 2025年第二次临时股东会的 法 律 意 见 书 江苏艾迪药业股份有限公司: 根据《中华人民共和国公司法》(以下简称"《公司法》")、《中华人民 共和国证券法》《上市公司股东会规则》和《上海证券交易所科创板上市公司自 律监管指引第1号 -- 规范运作》等法律、法规和规范性文件以及《公司章程》 的规定,本所受公司委托,指派本所律师出席公司 2025年第二次临时股东会, 并就本次股东会的召集、召开程序、出席会议人员资格、召集人资格、表决程序 以及表决结果的合法有效性等事项出具法律意见。 为出具本法律意见书,本所律师对本次股东会所涉及的有关事项进行了审 查,查阅了相关会议文件,并对有关问题进行了必要的核查和验证。 本所律师同意将本法律意见书随公司本次股东会决议一并公告,并依法对本 法律意见书承担相应的责任。 本所律师根据相关法律、法规和规范性文件的要求,按照律师行业公认的业 务标准、道德规范和勤勉尽责精神,出具法律意见如下: 一、关于本次股东会的召集、召开程序 1、本次股东会的召集 本次股东会由董事会召集。2025年6月27日,公司召开了第三届董事会第 四次会议 ...

证券代码：688488 证券简称：艾迪药业 公告编号：2025-037 江苏艾迪药业股份有限公司 2025年第二次临时股东会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一） 股东会召开的时间：2025 年 7 月 14 日 （二） 股东会召开的地点：南京市玄武区玄武大道 699-18 号百家汇社区 20 栋 5 楼 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 133 | | --- | --- | | 普通股股东人数 | 133 | | 2、出席会议的股东所持有的表决权数量 | 213,859,404 | | 普通股股东所持有表决权数量 | 213,859,404 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比 | 50.8241 | | 例（%） | | | 普通股股东所持有表决权数量占公司表决权数量的比例（%） | 50.82 ...

股及股份变更查询证明》及《股东股份变更明细清单》，在本次激励计划自查期 间，有 9 名核查对象存在公司股票交易行为，其余人员在自查期间内均不存在买 卖公司股票的行为。 经上述核查对象书面承诺，其在自查期间内买卖股票的行为系基于对二级市 场交易情况自行判断而进行的操作，与公司本次激励计划的内幕信息无关。在本 "核查对象"）。 划首次公开披露前六个月内买卖公司股票情况进行了查询，并由中国证券登记结 算有限公司上海分公司出具了书面的查询证明。 二、核查对象买卖公司股票情况说明 法律法规和规范性文件，公司通过中国证券登记结算有限责任公司上海分公司对 本次激励计划的内幕信息知情人和激励对象在本次激励计划草案公开披露前 6 个月内（即 2024 年 12 月 28 日至 2025 年 6 月 27 日，以下简称"自查期间"）买 卖公司股票的情况进行了自查，具体情况如下： 一、核查的范围与程序 《上市公司 信息披露管理办法》及公司内部制度的有关规定，公司对 2025 年股票期权激励 计划（以下简称"本次激励计划"）采取了充分必要的保密措施，对本次激励计 划的内幕信息知情人进行了登记。根据《管理办法》《上海证券交易所科创板股 ...

证券代码：688488 证券简称：艾迪药业 公告编号：2025-037 江苏艾迪药业股份有限公司 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ? 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一） 股东会召开的时间：2025 年 7 月 14 日 （二） 股东会召开的地点：南京市玄武区玄武大道 699-18 号百家汇社区 20 栋 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： 普通股股东人数 133 普通股股东所持有表决权数量 213,859,404 例（%） 普通股股东所持有表决权数量占公司表决权数量的比例（%） 50.8241 （四） 表决方式是否符合《公司法》及公司章程的规定，会议主持情况等。 本次股东会由公司董事会召集，董事长傅和亮先生主持，采用现场投票与网 络投票相结合的方式召开。本次会议的召集、召开及表决方式符合《中华人民共 和国公司法》《上海证券交易所科创板股票上市规则》及《公司章程》的相关规 定。 （五） 公司董事、监事和董事 ...

及激励对象买卖公司股票情况的自查报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 江苏艾迪药业股份有限公司（以下简称"公司"）于 2025 年 6 月 27 日召开 了第三届董事会第四次会议、第三届监事会第四次会议，审议通过了《关于公司 ＜2025 年股票期权激励计划（草案）＞及其摘要的议案》等相关议案，并于 2025 年 6 月 28 日在上海证券交易所网站（www.sse.com.cn）披露了相关公告。 根据《上市公司股权激励管理办法》（以下简称"《管理办法》"）、《上市公司 信息披露管理办法》及公司内部制度的有关规定，公司对 2025 年股票期权激励 计划（以下简称"本次激励计划"）采取了充分必要的保密措施，对本次激励计 划的内幕信息知情人进行了登记。根据《管理办法》《上海证券交易所科创板股 票上市规则》《科创板上市公司自律监管指南第 4 号——股权激励信息披露》等 法律法规和规范性文件，公司通过中国证券登记结算有限责任公司上海分公司对 本次激励计划的内幕信息知情人和激励对象在本次激励计划草案公开披露前 6 个月 ...

Core Insights - The report emphasizes the flourishing approval of new drugs and highlights the importance of focusing on technological tracks and opportunities within the industry chain [1][5] - It suggests a dual growth strategy combining internal and external growth, particularly in the context of the imminent patent cliff for IO1.0 and the increasing recognition of Chinese innovative pharmaceutical companies globally [5] Industry Overview - The report notes a significant recovery in domestic healthcare policies, including the integration of commercial insurance into the medical insurance system and the inclusion of high-priced innovative drugs in the Class B medical insurance catalog [5] - The overall revenue growth rate for chemical pharmaceutical companies in 2024 is projected at 4.10%, a substantial increase from 0.24% in 2023, while the net profit growth rate is expected to be 51.66% [12][15] Investment Opportunities - Short-term focus is recommended on certain tracks with high certainty, such as IO+ADC, while long-term investments should target new technologies with significant potential, including small nucleic acids and CAR-T [5] - The report categorizes various technological tracks for investment, including combinations of PD-1 with other mechanisms and innovative solutions for unmet clinical needs [5] Company Valuations - The report provides a comparative valuation of unprofitable innovative pharmaceutical companies, highlighting their market capitalizations and projected revenues for 2024 to 2027 [6] - It also presents a comparative valuation of profitable innovative pharmaceutical companies, detailing their market capitalizations and projected net profits for the same period [8] Performance Review - The report reviews the performance of pharmaceutical companies in 2024 and Q1 2025, noting that while the overall industry faced temporary pressure, gross profit margins have steadily improved [12][15] - It highlights that many small and mid-cap innovative pharmaceutical companies have turned profitable in Q1 2025, indicating a positive trend in the sector [18]

Group 1 - The pharmaceutical industry in Jiangsu province is increasingly adopting a "go global" strategy, with banks like China Construction Bank (CCB) providing innovative financial services to support this initiative [1] - CCB Jiangsu branch is enhancing financial products and services to support the entire lifecycle of pharmaceutical companies, facilitating efficient cross-border transactions [1] - Eddy Pharmaceutical, a listed company focused on HIV drug development, is expanding into the African market while improving its domestic procurement processes through digital upgrades [2][3] Group 2 - CCB Yangzhou branch has formed a dedicated team to assist Eddy Pharmaceutical in optimizing its payment processes, leading to significant improvements in fund turnover efficiency [3] - In March 2025, Eddy Pharmaceutical successfully processed a payment of 10 million yuan through CCB's supply chain products, ensuring stable raw material supply and enhancing its reputation in the supply chain [3] - CCB Jiangsu branch has provided over 50 million yuan in credit support to Eddy Pharmaceutical, facilitating its international expansion efforts [3] Group 3 - Yuyue Group is actively expanding its international market presence, with CCB Zhenjiang branch providing substantial financial support, including a 3 billion yuan loan for acquisitions [4] - As of March 2025, CCB Zhenjiang branch has granted a total credit of 2.64 billion yuan to Yuyue Group, enabling the company to overcome barriers in overseas markets [4] - Yuyue Group's subsidiary, Juyue Medical, has secured a credit line of 60 million yuan from CCB Zhenjiang branch, further supporting its operational needs [4] Group 4 - CCB Lianyungang branch has been closely monitoring a well-known pharmaceutical group, assisting in resolving a cross-border RMB transaction that had been pending for nearly a year due to compliance issues [6][7] - The bank conducted a rapid compliance review and successfully processed the transaction within 48 hours, thereby maintaining the company's international business reputation [6][7] - This collaboration exemplifies CCB's commitment to supporting pharmaceutical companies in their international endeavors through effective cross-border RMB services [7]